Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3756MR)

This product GTTS-WQ3756MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3756MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10161MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ6491MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ15991MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ13021MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ2639MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ12104MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MOR-03087
GTTS-WQ14531MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ1746MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW